Compounds for inhibiting LY6K and methods of using same
AssigneeThe Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
InventorGeeta Upadhyay
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to compounds that inhibit Ly6K. Also disclosed are methods of using such compounds to inhibit activity of Ly6K protein in a cell, to inhibit cell proliferation, to modulate expression of a gene in a cell, to reduce suppression of the immune response to cancer in a subject, to decrease tumorigenic growth of a cancer in a subject, and to treat or prevent in a subject a disorder mediated by Ly6K protein.
Claims21
A method for treating triple-negative breast cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of Compound I:
- or a pharmaceutically acceptable salt thereof,
- and a therapeutically effective amount of a PD-L1 inhibitor or a PD-1 inhibitor.
A method for treating an Ly6K-positive cancer or tumor in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of Compound I:
- or a pharmaceutically acceptable salt thereof,
- and a therapeutically effective amount of a PD-L1 inhibitor or a PD-1 inhibitor.
A method of reducing suppression of immune response to cancer in a subject, comprising administering to the subject an agent under conditions effective to reduce suppression of immune response to cancer in the subject, wherein the agent is Compound I:
- or a pharmaceutically acceptable salt thereof,
- and administering a PD-L1 inhibitor or a PD-1 inhibitor.
A method of inhibiting tumorigenic growth of a Ly6K-positive cancer or tumor in a subject, comprising administering an agent to the subject under conditions effective to inhibiting tumorigenic growth of a cancer in the subject, wherein the agent is Compound I:
- or a pharmaceutically acceptable salt thereof,
- and administering a PD-L1 inhibitor or a PD-1 inhibitor.
A method of treating, or preventing recurrence of, a disorder mediated by Ly6K protein in a subject in need thereof, the method comprising:
- administering a therapeutically effective amount of Compound I:
- or a pharmaceutically acceptable salt thereof,
- and a therapeutically effective amount of a PD-L1 inhibitor or a PD-1 inhibitor.
A method for modulating a tumor microenvironment in a subject in need thereof, comprising reducing myeloid-derived suppressor cells by administering to the subject a therapeutically effective amount of Compound I:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.